May 3rd 2024
Findings from a real-world study identified that venetoclax was a safe treatment option and did not lead to higher rates of death for patients with chronic lymphocytic leukemia who were diagnosed with COVID-19.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Ibrutinib Combination Significantly Reduces Progression in CLL
June 4th 2015The combination of ibrutinib with bendamustin plus rituximab (BR) demonstrated a significant improvement in progression-free survival compared with BR alone in patients with pretreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More
Bcl-2 Inhibitor Venetoclax Granted Breakthrough Therapy Designation for CLL
May 8th 2015Venetoclax (GDC-0199/ABT-199), a Bcl-2 inhibitor, has been granted a breakthrough therapy designation by the FDA for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The designation is specific to those patients who harbor a 17p deletion (del[17p]).
Read More
Combining Ofatumumab With Chemotherapy Delays Progression in CLL
April 29th 2015Topline findings from the phase III COMPLEMENT 2 study indicated that treatment with ofatumumab (Arzerra) plus fludarabine and cyclophosphamide significantly improved progression-free survival (PFS) compared with fludarabine and cyclophosphamide alone in patients with relapsed chronic lymphocytic leukemia (CLL).
Read More
Ibrutinib Regimen Delays Disease Progression in Phase III CLL Trial
March 17th 2015Combination therapy with ibrutinib plus bendamustine and rituximab significantly extended progression-free survival compared with BR alone in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma enrolled in the phase III HELIOS trial.
Read More
Winter Hematology Meeting Highlighted by Talks on Immunotherapy, Personalized Medicine
February 21st 2015Experts on hematologic malignancies will convene for the 19th Annual International Congress on Hematologic Malignancies, from February 20-21 in Miami, Florida, to provide insight into recent developments in the treatment of the diseases.
Read More
Upfront Fulvestrant Improves OS Compared With Anastrozole in HR-Positive MBC
December 13th 2014Fulvestrant (Faslodex) improved overall survival (OS) by 5.7 months compared with anastrozole as a frontline treatment for postmenopausal women with HR-positive metastatic breast cancer. These findings from the phase II FIRST trial were presented at the 2014 San Antonio Breast Cancer Symposium.
Read More
Frontline Idelalisib Monotherapy Shows 90% Response Rate in Elderly Patients With CLL, SLL
December 8th 2014Idelalisib monotherapy shows activity in treatment-naïve patients ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) — nearly 90% of patients enrolled in a phase II study demonstrated a partial response.
Read More
Cirmtuzumab Blocks Ovarian Cancer Metastasis in Preclinical Study
November 18th 2014The monoclonal antibody cirmtuzumab, currently in clinical trials to treat CLL, targets ROR1 on the surface of cancerous B cells, and the agent may have a wider reach in the treatment of ovarian and other cancers.
Read More
New Treatments for AML Remain Elusive, But Researchers Are Undeterred
November 6th 2014When Gail J. Roboz, MD, took the stage Wednesday to give her talk on what’s ahead in the treatment of acute myeloid leukemia (AML), she admitted feeling a little jealousy toward her colleagues in the lymphoid diseases.
Read More
CAR Therapy CTL019 Elicits Complete Remissions in ALL
October 20th 2014The investigational chimeric antigen receptor (CAR) therapy CTL019 elicited complete remissions in 27 of 30 pediatric and adult patients (90%) with relapsed/refractory acute lymphoblastic leukemia (ALL) in 2 pilot trials.
Read More
Progression on Ibrutinib With the Acquisition of Resistance Mutations
July 26th 2014Jennifer Woyach, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the association of disease progression on ibrutinib therapy with the acquisition of resistance mutations as seen at The Ohio State University Comprehensive Cancer Center.
Watch